Impact of Hereditary Angioedema (HAE) Attacks on Quality of Life and Activities of Daily Living

Busse PJ, Caballero T, van Kooten S, Danese S, Goga L

ACAAI 2022

Real-World Treatment Burden Associated with Parenteral On-Demand Therapies for Hereditary Angioedema

Tachdjian R, Savic S, Fridman M, Frade J, Audhya PK, Fasehun M

ACAAI 2022

Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On Demand Treatment for Hereditary Angiodema

Davie R, Edwards H, Evans D, Hodgson S, Stocks M, Smith A, Rushbrooke L, Pethen S, Roe M, Clark D, McEwan P, Hampton S

PMID: 36251573

Absorption, metabolism, and excretion of [14C]-sebetralstat (KVD900 following a single oral does in healthy male participants

Mutch P, Bashir M, Jung B, Yi P, Iverson M

PMID: 36200371

The Global and Regional Impact of Hereditary Angioedema (HAE) Attacks on Mental Health, Activities of Daily Living and Quality of Life

Busse PJ, Caballero T, van Kooten S, Danese S, Goga L

2022 HAEi Global Leadership Workshop

Patient Perspectives on an Optimal Outcome Measure to Assess Efficacy in the Acute Treatment of Hereditary Angioedema Attacks

Riedl MA, Cohn DM, Aygören-Pürsün E, Zanichelli A, Farkas H, Bernstein JA, Lumry WR, Smith MD, Yea CM, Audhya PK

2022 HAEi Global Leadership Workshop

Pharmacology of KVD824, an Investigational Drug for Prophylaxis of HAE

Grivcheva-Panovska V, Smith MD, Duckworth EJ, Hampton SL, Yea CM, Mutch P, Iverson M, Hansen E, Feener EP

BRADYKININ SYMPOSIUM

Sebetralstat Effectiveness in the Treatment of Hereditary Angioedema Attacks Rated Mild or Moderate at Baseline in the Phase 2 Trial

Longhurst HJ, Smith MD, Yea CM, Audhya PK

ASCIA 2022

Efficacy and Safety of the Oral Plasma Kallikrein Inhibitor Sebetralstat (KVD900) in Adolescent and Adult Patients With Hereditary Angioedema: Phase 3 Trial Design

Aygören-Pürsün E, Zanichelli A, Cohn DM, Farkas H, Bernstein JA , Audhya PK, Smith MD, Yea CM, Lumry WR, Riedl MA, Maurer M

EAACI 2022

Novel Oral Small Molecule FXIIa Inhibitor Blocks Contact System Activation In Vivo

Clermont A

EAACI 2022